Trading Report: Today, Juno Therapeutics Inc (JUNO) PT Set at $34.00 by JPMorgan Chase & Co.

Today, Juno Therapeutics Inc (JUNO) PT Set at $34.00 by JPMorgan Chase & Co.

Juno Therapeutics Inc (NASDAQ:JUNO) has been given a $34.00 price target by JPMorgan Chase & Co. in a report issued on Thursday. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s target price indicates a potential upside of 47.76% from the company’s previous close.

Other analysts have also recently issued reports about the company. SunTrust Banks Inc. cut Juno Therapeutics from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $48.00 to $25.00 in a research report on Friday. FBR & Co reaffirmed an “outperform” rating and set a $61.00 price objective on shares of Juno Therapeutics in a research report on Saturday, October 15th. BTIG Research raised Juno Therapeutics from a “sell” rating to a “neutral” rating in a research report on Thursday, November 3rd. Zacks Investment Research raised Juno Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Finally, Vetr raised Juno Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 23rd. Six investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Juno Therapeutics presently has an average rating of “Buy” and an average target price of $41.13.

Shares of Juno Therapeutics (NASDAQ:JUNO) traded up 1.99% during mid-day trading on Thursday, hitting $23.01. The company had a trading volume of 3,843,132 shares. The firm has a 50-day moving average price of $27.52 and a 200 day moving average price of $32.91. Juno Therapeutics has a 12 month low of $19.41 and a 12 month high of $57.82. The firm’s market capitalization is $2.36 billion.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.05. The company earned $20.80 million during the quarter, compared to analysts’ expectations of $10.98 million. The firm’s revenue was up 1200.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.26) EPS. On average, equities research analysts forecast that Juno Therapeutics will post ($2.54) earnings per share for the current fiscal year.

In other Juno Therapeutics news, EVP Robert Azelby sold 12,921 shares of the firm’s stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $24.14, for a total transaction of $311,912.94. Following the completion of the transaction, the executive vice president now owns 48,640 shares of the company’s stock, valued at $1,174,169.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Hans Edgar Bishop sold 84,035 shares of the firm’s stock in a transaction on Wednesday, September 21st. The stock was sold at an average price of $30.28, for a total value of $2,544,579.80. Following the transaction, the chief executive officer now directly owns 2,518,537 shares of the company’s stock, valued at approximately $76,261,300.36. The disclosure for this sale can be found here.

A number of institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its position in Juno Therapeutics by 0.4% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,698 shares of the biopharmaceutical company’s stock valued at $711,000 after buying an additional 98 shares during the last quarter. Boyer & Corporon Wealth Management LLC increased its position in Juno Therapeutics by 0.9% in the second quarter. Boyer & Corporon Wealth Management LLC now owns 12,579 shares of the biopharmaceutical company’s stock valued at $484,000 after buying an additional 115 shares during the last quarter. Profund Advisors LLC increased its position in Juno Therapeutics by 0.4% in the second quarter. Profund Advisors LLC now owns 39,877 shares of the biopharmaceutical company’s stock valued at $1,533,000 after buying an additional 148 shares during the last quarter. Legal & General Group Plc increased its position in Juno Therapeutics by 5.9% in the second quarter. Legal & General Group Plc now owns 5,470 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 306 shares during the last quarter. Finally, BlackRock Investment Management LLC increased its position in Juno Therapeutics by 1.3% in the third quarter. BlackRock Investment Management LLC now owns 25,635 shares of the biopharmaceutical company’s stock valued at $769,000 after buying an additional 320 shares during the last quarter.

Juno Therapeutics Company Profile

Related posts

Leave a Comment